Highest-materiality recent filing
Fuse Medical voluntarily deregisters common stock, suspends SEC reporting
Filed Form 15 to voluntarily deregister common stock and suspend Exchange Act reporting effective Sept 27, 2023.
Fuse Medical Q2 2023 net income $307,588 vs loss of $322,936 a year ago
Revenue rose 7% to $5.0M from $4.7M in Q2 2022.
Fuse Medical reports FY 2022 net income of $3.1M, swing from prior-year loss; revenue down 9%
Net revenue $18.6M (-9% YoY); gross profit margin improved to 62% from 58%.
Fuse Medical enters $5M secured revolving credit facility with CNH Finance, matures 2025
$5M revolving credit facility, maturity January 1, 2025; subject to borrowing base.
Fuse Medical obtains waiver of EBITDA default; loan limit cut to $2.55M, term extended to Feb 2022
Lender waived default for failing to meet $600K minimum EBITDA for trailing twelve months ended Sep 30, 2021.
Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.
Effective April 4, 2022, the Board of Directors of the Company (the “Board”) has appointed Lawrence S. Yellin as Chief Financial Officer (CFO) and Treasurer of the Company and as a member of the Board.
Effective April 4, 2022, John S. Gross ceased providing the Company with interim CFO services pursuant to the Company’s engagement agreement with CFO Consulting Partners, LLC.
On November 29, 2021, William E. McLaughlin, III resigned as Chief Financial Officer and as a Director of the Board of Fuse Medical, Inc. (the “Company”) as well as from all other positions Mr. McLaughlin held with the Company and its subsidiaries.
Max materiality 0.75 · Median 0.55 · Most common event earnings